| Literature DB >> 27376675 |
Olivier Bornert1, Patricia Peking2, Jeroen Bremer3, Ulrich Koller2, Peter C van den Akker3,4, Annemieke Aartsma-Rus5, Anna M G Pasmooij3, Eva M Murauer2, Alexander Nyström1.
Abstract
Genetic disorders affecting the skin, genodermatoses, constitute a large and heterogeneous group of diseases, for which treatment is generally limited to management of symptoms. RNA-based therapies are emerging as a powerful tool to treat genodermatoses. In this review, we discuss in detail RNA splicing modulation by antisense oligonucleotides and RNA trans-splicing, transcript replacement and genome editing by in vitro-transcribed mRNAs, and gene knockdown by small interfering RNA and antisense oligonucleotides. We present the current state of these therapeutic approaches and critically discuss their opportunities, limitations and the challenges that remain to be solved. The aim of this review was to set the stage for the development of new and better therapies to improve the lives of patients and families affected by a genodermatosis.Entities:
Keywords: RNA trans-splicing; antisense oligonucleotides; in vitro-transcribed mRNA; siRNA; skin
Mesh:
Substances:
Year: 2017 PMID: 27376675 PMCID: PMC5593095 DOI: 10.1111/exd.13141
Source DB: PubMed Journal: Exp Dermatol ISSN: 0906-6705 Impact factor: 3.960